Baird analyst Michael Ha said the weakness in Oscar Health (OSCR) following ts results is a buying opportunity and he expects the shares to trade back to around $18 in the near-term. Baird reiterated its Outperform rating and $28 price target on Oscar Health shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: